What is Pell Bio-Med Technology Co., Ltd.'s (6949.TW) StockRank?

MoatMap's StockRank for Pell Bio-Med Technology Co., Ltd. (6949.TW) is 39/100, with a Hold signal. This is a composite score combining Quality (37), Value (20), and Momentum (73) factor ranks across MoatMap's 20,000+ stock universe.

Does Pell Bio-Med Technology Co., Ltd. have an economic moat?

Pell Bio-Med Technology Co., Ltd. (6949.TW) has a Quality factor score of 37/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Pell Bio-Med Technology Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Pell Bio-Med Technology Co., Ltd. (6949.TW) is Hold, based on a StockRank of 39/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Pell Bio-Med Technology Co., Ltd. in?

Pell Bio-Med Technology Co., Ltd. (6949.TW) operates in the Healthcare sector, specifically the Biotechnology industry (Taiwan).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

6949.TW

HOLDREMOVE

Pell Bio-Med Technology Co., Ltd. · Healthcare · Taiwan · $1.8B · Avg Vol: $5M/d

StockRank

P/E (TTM)

—

ROE

-22.3%

D/E

0.1x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

An early-stage Taiwanese biotech company lacking the validated, large-scale manufacturing capacity and regulatory moats of established CDMOs.

COMPANY DESCRIPTION

Pell Bio-Med Technology Co., Ltd. is a biotechnology company specializing in cellular immunotherapy and regenerative medicine. The company develops advanced cell therapy products, including immune cell and stem cell therapies, targeting cancer and degenerative diseases. It operates state-of-the-art GTP (Good Tissue Practice) laboratories, positioning itself as a pioneer in Taiwan's emerging regenerative medicine sector.

FINANCIAL SUMMARY (USD)

Year	2021	2022	2023	2024	2025	CAGR
Revenue	—	0.5M	0.6M	0.6M	1.0M	22.4%
EPS	-0.18	-0.18	-0.27	-0.22	—	—
Shares	—	57.6M	57.6M	58.3M	59.3M	+2.9%
Debt	—	6.4M	5.5M	11.5M	7.5M	5.4%
Equity	—	25.3M	37.0M	37.3M	44.9M	21.1%
Op CF	—	-5.1M	-5.7M	-8.2M	-8.9M	—
Inv CF	—	-17.4M	-13.3M	-3.0M	-15.7M	—
Fin CF	—	24.3M	18.8M	19.4M	20.8M	—

PRICE (1Y)+22.5%

SMA 50SMA 200

$26.32

RSI (14)

75.3

52W High

$30.59

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

-25.0%25.8

ROE

-22.3%29.0

GP/Assets

-0.5%8.9

Op. Margin

-1393.8%6.0

FCF/Assets

-23.6%13.6

Piotroski

666.7

Int. Cover

-50.0x6.0

D/E Ratio

0.08x68.9

Current Ratio

9.60x86.3

Value

P/E (TTM)

—N/A

EV/EBITDA

-100.1x25.0

P/FCF

—N/A

P/B

18.0x6.2

P/S

1876.3x2.1

Div Yield

—N/A

Momentum

52W High %

86%93.5

RS 6M

72%96.7

SMA 50/200

1.41x96.8

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.8B

P/E (Forward)

—

Gross Margin

-38.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 6949.TW are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
6949.TW	Pell Bio-Med Technology Co., Ltd.(you)	$1.8B	39	HOLD
6547.TWO	Medigen Vaccine Biologics Corporation	$468M	32	SELL
4743.TWO	Oneness Biotech Co., Ltd.	$726M	11	STRONG SELL
4169.TW	TCM Biotech International Corp.	$387M	22	SELL
4147.TWO	TaiMed Biologics Inc.	$494M	15	STRONG SELL
6634.TWO	Sinew Pharma Inc.	$143M	35	SELL
4142.TW	Adimmune Corporation	$229M	25	SELL
6919.TW	CALIWAY BIOPHARMACEUTICALS CO L	$5.9B	5	STRONG SELL
4728.TWO	Sunmax Biotechnology Co., Ltd.	$648M	78	BUY
6589.TW	EirGenix Inc.	$443M	8	STRONG SELL

Peer medians: ROE 3.6% · P/E 16.2x · Gross margin 42.1%

Pell Bio-Med Technology Co., Ltd. (6949.TW) — Stock Score Summary

Pell Bio-Med Technology Co., Ltd. (6949.TW) has a MoatMap StockRank of 39/100 based on Quality (37/100), Value (20/100), and Momentum (73/100) factor scores. The current signal is HOLD. An early-stage Taiwanese biotech company lacking the validated, large-scale manufacturing capacity and regulatory moats of established CDMOs.

Key Financial Metrics

Price	$26.32
Market Cap	$1.8B
Price/Book	18.02
Return on Equity	-22.3%
Return on Invested Capital	-25.0%
Debt/Equity	8.18
Gross Margin	-38.0%
Operating Margin	-1393.8%
Revenue Growth	-46.7%
Free Cash Flow	$-499K

Pell Bio-Med Technology Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (Taiwan).

Frequently Asked Questions

What is Pell Bio-Med Technology Co., Ltd.’s (6949.TW) StockRank?: MoatMap’s StockRank for Pell Bio-Med Technology Co., Ltd. (6949.TW) is 39/100, with a Hold signal. It is a composite of Quality (37), Value (20), and Momentum (73) factor ranks across MoatMap’s 20,000+ stock universe.
Does Pell Bio-Med Technology Co., Ltd. have an economic moat?: Pell Bio-Med Technology Co., Ltd. (6949.TW) has a Quality factor score of 37/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Pell Bio-Med Technology Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Pell Bio-Med Technology Co., Ltd. (6949.TW) is Hold, based on a StockRank of 39/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Pell Bio-Med Technology Co., Ltd. in?: Pell Bio-Med Technology Co., Ltd. (6949.TW) operates in the Healthcare sector, specifically the Biotechnology industry (Taiwan).